Health Tip: Coping With Winter Nosebleeds
-- Wintry climates and cold viruses can lead to frequent nosebleeds, says the National Hemophilia Foundation. To prevent nosebleeds during winter, the foundation suggests: Use a humidifier to moisturize the air. Use a nasal saline spray or... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 10, 2020 Category: General Medicine Source Type: news

Gene therapy shown to offer long-term benefits for people with Haemophilia A
(Queen Mary University of London) A breakthrough gene therapy treatment for Haemophilia A has been shown to offer long-term benefits that have already transformed the lives of 13 men in the UK. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 6, 2020 Category: International Medicine & Public Health Source Type: news

Gene Therapy May Be Long-Term Cure for Type of Hemophilia
Title: Gene Therapy May Be Long-Term Cure for Type of HemophiliaCategory: Health NewsCreated: 1/2/2020 12:00:00 AMLast Editorial Review: 1/3/2020 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - January 3, 2020 Category: Anesthesiology Source Type: news

Gene Therapy May Be Long-Term Cure for Type of Hemophilia
THURSDAY, Jan. 2, 2020 -- A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, early clinical trial results indicate. Patients who received the one-time intravenous therapy continue to have a more than... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 2, 2020 Category: General Medicine Source Type: news

Hepatitis gene therapy leads Bay Area trio of year-end FDA approval requests
Approaching the end of long drug-development journeys, these three Bay Area companies formally asked the FDA to approve potential treatments for hemophilia A, anemia in chronic kidney disease patients and migraines. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 23, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Hepatitis gene therapy leads Bay Area trio of year-end FDA approval requests
Approaching the end of long drug-development journeys, these three Bay Area companies formally asked the FDA to approve potential treatments for hemophilia A, anemia in chronic kidney disease patients and migraines. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 23, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Potential 1st Gene Therapy in Europe Directed at Any Type of Hemophilia Application to be Reviewed Under Accelerated Assessment SAN RAFAEL, Calif., Dec. 23, 2019 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN... Biopharmaceuticals, Regulatory BioMarin Pharmaceutical, valoctocogene roxaparvovec, hemophilia A, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2019 Category: Pharmaceuticals Source Type: news

BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A
SAN RAFAEL, Calif., Dec. 23, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 23, 2019 Category: Drugs & Pharmacology Source Type: news

Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together...
Source: Roche Media News - December 17, 2019 Category: Pharmaceuticals Source Type: news

Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together...
Source: Roche Investor Update - December 17, 2019 Category: Pharmaceuticals Source Type: news

Roche purchases shares in tender offer for Spark Therapeutics, Inc.
Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Spark, at a price of USD 114.50 per share in ca sh.  The tender offer expired at 5:00 p.m., New York City time, on 16 December 2019 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of appr...
Source: Roche Media News - December 17, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority
Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchas...
Source: Roche Media News - December 16, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority
             Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subjec...
Source: Roche Investor Update - December 16, 2019 Category: Pharmaceuticals Source Type: news

Highmark Establishes High-Performance Hemophilia Partnership
Highmark announced a new partnership focused on the treatment and management of hemophilia, which aims to ensure that members receive hemophilia drugs from organizations that meet rigorous performance...(PRWeb November 19, 2019)Read the full story at https://www.prweb.com/releases/highmark_establishes_high_performance_hemophilia_partnership/prweb16725465.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 19, 2019 Category: Pharmaceuticals Source Type: news

Putting a Price on Life: Is the Answer Outside Pharma?
 To cure the previously incurable we must take two giant steps: the first towards better understanding the science behind a cure, and the second towards ensuring accessibility for those people in need of the treatment.   Although there is still much to discover, we got the science right some time ago. The first gene replacement therapy – Gendicine (Shenzhen SiBiono GeneTech) – was approved in China in 2003 and has been successfully administered to more than 30,000 patients with head and neck squamous cell carcinoma. A single dose of this medication costs $400.  Another example of early ...
Source: EyeForPharma - November 4, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

1,125,000 Men/Boys Expected to Have Hemophilia Worldwide
Prevalence of all severities of hemophilia A and hemophilia B estimated at 17.1 and 3.8 cases per 100,000 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 10, 2019 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pediatrics, Journal, Source Type: news

1,125,000 Men/Boys Expected to Have Hemophilia Worldwide
TUESDAY, Sept. 10, 2019 -- The expected number of patients with hemophilia worldwide is 1,125,000 male patients, with 418,000 severe cases, according to research published online Sept. 10 in the Annals of Internal Medicine. Alfonso Iorio, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2019 Category: Pharmaceuticals Source Type: news

Hemophilia disease 3 times more prevalent than previously thought, study finds
In a new study published Monday, researchers at Hamilton's McMaster University say more than 1,125,000 men around the world have hemophilia, and 418,000 of those have a severe version of the mostly undiagnosed disease. (Source: CBC | Health)
Source: CBC | Health - September 9, 2019 Category: Consumer Health News Tags: News/Canada/Hamilton Source Type: news

NHS to fund 'life changing' haemophilia drug
Emicizumab mimics the action of factor VIII to stem uncontrolled bleeds Related items fromOnMedica Child health should be election priority say experts and public Government launches its Child Health Strategy Cash-injection for sick children UK lagging behind other comparable countries on young people ’s health England falling behind on child health (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 22, 2019 Category: UK Health Source Type: news

'Trailblazing' treatment that prevents bleeds in haemophiliacs will be available on NHS England
Emicizumab, which mimics the missing protein, can be injected under the skin as little as every two weeks. It is now available after NHS England agreed to fund the drug, sold under the brand name Hemlibra. (Source: the Mail online | Health)
Source: the Mail online | Health - August 21, 2019 Category: Consumer Health News Source Type: news

New drug for people who can bleed uncontrollably
NHS England is funding a new treatment for patients with severe haemophilia A. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 21, 2019 Category: Consumer Health News Source Type: news

Life-changing drug to stop deadly bleeding available on the NHS
NHS England is to fund a life-changing treatment for thousands of people with severe haemophilia, which will dramatically cut their risk of life-threatening bleeds and reduce treatment time. (Source: NHS Networks)
Source: NHS Networks - August 21, 2019 Category: UK Health Source Type: news

Bayer recalls two lots of mislabeled hemophilia A med
The drugmaker is voluntarily recalling two lots that were filled with factor VIII hemophilia A treatment Jivi but were labeled as containing hemophilia treatment Kogenate FS (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 23, 2019 Category: Pharmaceuticals Source Type: news

Boy with bruises whose parents were 'accused of abusing him' diagnosed with a rare blood condition
Jack Fearns, of Cheshire, was six months old when his parents, Tom and Darryl-Anne Ferns, felt interrogated by doctors. Jack was diagnosed with haemophilia. (Source: the Mail online | Health)
Source: the Mail online | Health - July 19, 2019 Category: Consumer Health News Source Type: news

Dosing Differences Opined for Costly Hemophilia Option Dosing Differences Opined for Costly Hemophilia Option
Achieving the goal of zero bleeds as patients pursue active lives will require divergent dosing, according to PROPEL trial investigators who evaluated whether more exposure to FVIII improves outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 12, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Local biotechs UniQure, Casebia step up race for new hemophilia drugs
The race for new, long-lasting treatments for the two most common forms of hemophilia heated up this week as two local gene therapy companies presented trial data for drugs in development alongside Big Pharma players. Lexington biotech UniQure N.V. (Nasdaq: QURE) — which has been the subject of M&A rumors in recent weeks, per Bloomberg — presented new data earlier this week on its treatment for hemophilia B, a form of the rare, genetic blood disease which affects the body’s ability to form… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 11, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

BioMarin Appoints Pharmaceutical Veteran and Former J and J Executive, Liz McKee Anderson, to Board of Directors
SAN RAFAEL, Calif., July 9, 2019 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of pharmaceutical veteran and forme... Biopharmaceuticals, Personnel BioMarin Pharmaceutical, valoctocogene roxaparvovec, hemophilia A, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 9, 2019 Category: Pharmaceuticals Source Type: news

Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
Roche today announced new data for Hemlibra ® (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on 6-10 July in Melbourne, Australia. (Source: Roche Media News)
Source: Roche Media News - July 9, 2019 Category: Pharmaceuticals Source Type: news

Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
Roche today announced new data for Hemlibra ® (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on 6-10 July in Melbourne, Australia. (Source: Roche Investor Update)
Source: Roche Investor Update - July 9, 2019 Category: Pharmaceuticals Source Type: news

Contaminated blood scandal: Victims reveal 'coalition of secrecy'
Haemophiliac Alistair Bennett contracted HIV/Aids from a contaminated blood product. He died aged 22. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 2, 2019 Category: Consumer Health News Source Type: news

New plasma donation center takes space on Gadsden Highway
A new plasma donation center is set to open on July 10, at 222 Gadsden Highway in Birmingham.   OctaPharma is a Lachen, Switzerland-based company that allows people to donate plasma for medical production.  “OctaPharma converts donated plasma into plasma protein products used in more than 100 countries to treat life-threatening congenital and acquired diseases such as hemophilia A and B, immune deficiency syndromes, Rh disease in newborns and burn injuries,” Dr. David J. Aarons, medical director… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 18, 2019 Category: Biotechnology Authors: Tyler Patchen Source Type: news

Recombinant factor  VIII-Fc good choice in haemophilia A
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2019 Category: Drugs & Pharmacology Source Type: news

BioMarin says data shows hemophilia gene therapy effects could wane
BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years. (Source: Reuters: Health)
Source: Reuters: Health - May 29, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last?
A potential one-shot-and-you're-done hemophilia A treatment from BioMarin Pharmaceutical Inc. will target regulatory approval in the United States and Europe after showing dramatic decreases in bleeding during clinical trials. But in a competitive market to find the next big and expensive treatment to help — or even cure — hemophilia A patients, questions linger around how long the treatment sticks with patients. BioMarin (NASDAQ: BMRN) apparently didn't allay those concerns Tuesday: The San… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 28, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last?
A potential one-shot-and-you're-done hemophilia A treatment from BioMarin Pharmaceutical Inc. will target regulatory approval in the United States and Europe after showing dramatic decreases in bleeding during clinical trials. But in a competitive market to find the next big and expensive treatment to help — or even cure — hemophilia A patients, questions linger around how long the treatment sticks with patients. BioMarin (NASDAQ: BMRN) apparently didn't allay those concerns Tuesday: The San… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 28, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
Timing of Regulatory Submissions to Be Determined in 3Q 2019 Conference Call and Webcast to be Held Tuesday, May 28, 2019 at 8:00 AM Eastern SAN RAFAEL, Calif., May 28, 2019 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (... Biopharmaceuticals BioMarin Pharmaceutical, valoctocogene roxaparvovec, hemophilia A, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 28, 2019 Category: Pharmaceuticals Source Type: news

Researchers ready B cells for novel cell therapy
(Seattle Children's) Scientists at Seattle Children's Research Institute are paving the way to use gene-edited B cells -- a type of white blood cell in the immune system -- to treat a wide range of potential diseases that affect children, including hemophilia and other protein deficiency disorders, autoimmune diseases, and infectious diseases. If successful, their research would open the door to offering this experimental cell therapy as the first-of-its-kind in clinical trials at Seattle Children's in as soon as five years. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 2, 2019 Category: Infectious Diseases Source Type: news

PHARMAC funds longer-acting treatments for haemophilia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2019 Category: Drugs & Pharmacology Source Type: news

Enzyre Appoints Dirk Pollet as Chief Executive Officer
Awarded €2M grant and completes seed financing to develop high-precision point-of-care Hemophilia Biochip device NIJMEGEN, Netherlands, April 30, 2019 -- (Healthcare Sales & Marketing Network) -- Enzyre, which is developing breakthrough ambulant diagno... Diagnostics, Personnel Enzyre , Hemophilia Biochip (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2019 Category: Pharmaceuticals Source Type: news

St. Jude prepares to launch global hemophilia gene therapy trial
St. Jude is trying to establish a gene therapy program to bring next-level treatment options to patients in under-resourced countries. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 23, 2019 Category: Biotechnology Authors: Jason Bolton Source Type: news

St. Jude prepares to launch global hemophilia gene therapy trial
St. Jude is trying to establish a gene therapy program to bring next-level treatment options to patients in under-resourced countries. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 23, 2019 Category: American Health Authors: Jason Bolton Source Type: news

Cameroon: World Hemophilia Day - Population Schooled On Treatment Mechanisms
[Cameroon Tribune] Sensitisation activities to commemorate the day end today in Yaounde. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 18, 2019 Category: African Health Source Type: news

Roche reports a strong start in 2019 and raises the outlook for the full-year
In the first three months of 2019, Group sales rose 8% to CHF 14.8 billion. Sales in the Pharmaceuticals Division increased 10% to CHF 11.9 billion. Key growth drivers were the multiple sclerosis medicine Ocrevus and cancer medicines Perjeta and Tecentriq as well as the new haemophilia medicine Hemlibra. (Source: World Pharma News)
Source: World Pharma News - April 18, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

World Hemophilia Day: Sanofi Genzyme donation impacts patients across the globe
On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of unmet needs for patients. Hemophilia is a rare, genetic bleeding disorder in which the ability of a person's blood to clot is impaired, which can lead to bleeding episodes that can cause pain, irreversible joint damage, and life-threatening hemorrhages. (Source: World Pharma News)
Source: World Pharma News - April 17, 2019 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Gene-based factor VIIa prevents bleeding episodes in animals with hemophilia
(Children's Hospital of Philadelphia) Hematology researchers have further refined how a treatment currently used on an urgent basis to control bleeding in hemophilia patients holds promise as a preventive treatment as well. A study in animals may set the stage for a new therapy for a subset of patients with hemophilia who now develop antibodies to the standard maintenance treatment and then require on-demand 'bypass' therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2019 Category: International Medicine & Public Health Source Type: news

Cochrane's 30 under 30: Ndi Euphrasia Ebai-Atuh
Cochrane is made up of  13,000 members and over 50,000 supporters come from more than 130 countries, worldwide. Our volunteers and contributors are researchers, health professionals, patients, carers, people passionate about improving health outcomes for everyone, everywhere.Cochrane is an incredible community of people who all play their part in improving health and healthcare globally. We believe that by putting trusted evidence at the heart of health decisions we can achieve a world of improved health for all.  Many  of our contributors are young people working with Cochrane ...
Source: Cochrane News and Events - April 12, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news

European Commission approves Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII deficiency, FVIII (Source: Roche Media News)
Source: Roche Media News - March 14, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII deficiency, FVIII (Source: Roche Investor Update)
Source: Roche Investor Update - March 14, 2019 Category: Pharmaceuticals Source Type: news

Roche to buy Spark Therapeutics
Roche Holding has entered a definitive merger agreement with Spark Therapeutics, as the Swiss drugmaker seeks to expand its ability to treat rare diseases through gene therapies, as well as build its hemophilia portfolio. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 25, 2019 Category: Pharmaceuticals Source Type: news

Roche to buy gene therapy specialist Spark in $4.3 billion deal
Roche Holding AG said on Monday it will buy Spark Therapeutics in a $4.3 billion deal, as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy. (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news